Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor.
10.3779/j.issn.1009-3419.2019.10.03
- Author:
Hanping WANG
1
;
Xiaoxiao GUO
2
;
Jiaxin ZHOU
3
;
Lian DUAN
4
;
Xiaoyan SI
1
;
Li ZHANG
5
;
Yue LI
6
;
Xiaowei LIU
7
;
Mengzhao WANG
1
;
Juhong SHI
1
;
Li ZHANG
1
Author Information
1. Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
3. Department of Rheumatism and Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
4. Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
5. Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
6. Department of Digestive Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
7. Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Checkpoint inhibitor pneumonitis;
Immune checkpoint inhibitor;
Immunotherapy-related toxicities
- From:
Chinese Journal of Lung Cancer
2019;22(10):621-626
- CountryChina
- Language:Chinese
-
Abstract:
The increasing use of immunocheckpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immunocheckpoint inhibitors, mainly activated T-cell immunity, may attack normal tissues and organs of the human body and lead to a variety of adverse effects. In the lung, they could induce checkpoint inhibitor associated pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and had a potentially fatal risk if it was not being properly treated. We will summarize the characteristics of CIP and give our advice on how to manage immunocheckpoint inhibitor associated pneumonitis.
